Skip to main content

J.P.Morgan Healthcare Conference JPM23: Biotech Rally Favors Smaller Caps

Large cap biopharmas that outperformed in 2022 were generally weak last week from profit-taking and portfolio rebalancing.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.